EPA Tightens Limits on a Cancer-Causing Chemical Used to Sterilize Medical Equipment
WASHINGTON — The Environmental Protection Agency is imposing stricter limits on a chemical used to sterilize medical equipment after finding a higher-than-expected cancer risk at facilities that use ethylene oxide to clean billions of devices including catheters and syringes. A rule finalized Thursday will reduce ethylene oxide emissions by about 90% by targeting nearly 90 commercial sterilization facilities across the country, the EPA said. The companies will also have to test for the antimicrobial chemical in the air and make sure their pollution controls are working properly. [time-brightcove not-tgx=”tru...
Source: TIME: Health - March 15, 2024 Category: Consumer Health News Authors: Matthew Daly/AP Tags: Uncategorized healthscienceclimate wire Source Type: news

FDA Approves First CAR-T for Chronic Lymphocytic Leukemia
(MedPage Today) -- The FDA granted accelerated approval to lisocabtagene maraleucel (liso-cel, Breyanzi) for pretreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), drugmaker Bristol Myers Squibb announced on Thursday... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 15, 2024 Category: American Health Source Type: news

U.S. FDA Approves Bristol Myers Squibb ’s Breyanzi as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
PRINCETON, N.J.--(BUSINESS WIRE) Mar 14, 2024 -- Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 14, 2024 Category: Drugs & Pharmacology Source Type: news

Florida entrepreneur documents his heartbreaking battle with lymphoma in his 20s - as doctors warn cancer patients keep getting younger: 'I had to sit with my father and write my will at 25'
A 25-year-old (pictured) from Florida diagnosed with lymphoma is documenting his experience as he battles cancer - giving people an intimate look at his journey. (Source: the Mail online | Health)
Source: the Mail online | Health - March 12, 2024 Category: Consumer Health News Source Type: news

B-Cell Lymphoma: Caring for Your Emotional Needs
There are many steps you can take to get control of the wide range of feelings that may rise up inside when you get a diagnosis of B-cell lymphoma. Learn how support from family and friends, exercise, and connecting with others who have your disease can help you manage your emotions. (Source: WebMD Health)
Source: WebMD Health - March 12, 2024 Category: Consumer Health News Source Type: news

What to Expect From a Stem Cell Transplant
Stem cell transplantation, in combination with traditional treatments, can improve outcomes for patients with multiple myeloma and non-Hodgkin's lymphoma. (Source: WebMD Health)
Source: WebMD Health - March 12, 2024 Category: Consumer Health News Source Type: news

Pfizer is betting big on cancer drugs to turn business around after Covid decline
Pfizer is ready to move on from Covid. Now, the company is betting on cancer drugs to help it regain its footing after a rocky year marked by the rapid decline of its Covid business. It just might take a while before that bet pays off. Pfizer pitched its deeper push into oncology during a…#pfizer #superbowl #rsv #seagen #astellaspharma #guggenheim #chrisboshoff #medicare #lymphomas #suneetvarma (Source: Reuters: Health)
Source: Reuters: Health - March 10, 2024 Category: Consumer Health News Source Type: news

Zanubrutinib Label Expands to Include RR Follicular Lymphoma Zanubrutinib Label Expands to Include RR Follicular Lymphoma
The Bruton ' s kinase inhibitors new follicular lymphoma indication is for combination use with obinutuzumab.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 8, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

BeiGene Announces FDA Accelerated Approval of Brukinsa for the Treatment of Relapsed or Refractory Follicular Lymphoma
BASEL, Switzerland& BEIJING& CAMBRIDGE, Mass.-- Mar 07, 2024 (BUSINESS WIRE)-- BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 7, 2024 Category: Drugs & Pharmacology Source Type: news

FDA grants accelerated approval to zanubrutinib for relapsed or refractory follicular lymphoma
On March 7, 2024, the Food and Drug Administration granted accelerated approval to zanubrutinib (Brukinsa, BeiGene USA, Inc.) with obinutuzumab for relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 7, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Novel Regimens Yield High Response Rates for Older, Hodgkin Lymphoma Patients
(MedPage Today) -- Older patients with classical Hodgkin lymphoma unsuitable for conventional chemotherapy had high rates of durable responses with two brentuximab vedotin (BV; Adcetris) regimens, one that omitted chemotherapy, a small prospective... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 7, 2024 Category: Hematology Source Type: news

Breast cancer fears for almost 1,500 women at 'very high risk' of disease after 'historic' blunder meant they weren't invited for annual NHS check-ups
The error meant women who received radiotherapy treatment for Hodgkin lymphoma between 1962 and 2003 were not contacted for annual breast cancer check ups. (Source: the Mail online | Health)
Source: the Mail online | Health - March 5, 2024 Category: Consumer Health News Source Type: news

‘I feel like myself again’: UCLA clinical trial offers hope for lymphoma patients
In June 2018, actor Hirotaka Matsunaga was supposed to be two weeks away from opening night of “The Swords of Sorrow: BURAI II,” a play set in 1800s Japan. The 39-year-old had been cast as the lead. It was the big break he had been working toward since he moved to the U.S. from Japan more than 20 years ago to pursue his dreams.But his cancer diagnosis and an unsuccessful course of chemotherapy had shut down the play.“Around November 2017, I had acute pain in my stomach for weeks, and it got so bad that it became difficult to eat,” Matsunaga said.After a particularly agonizing dinner, he checked himself into a hosp...
Source: UCLA Newsroom: Health Sciences - March 5, 2024 Category: Universities & Medical Training Source Type: news

Cleveland Clinic researchers uncover how virus causes cancer, point to potential treatment
Cleveland Clinic researchers have discovered a key mechanism used by Kaposi's sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV8), to induce cancer. The research points to effective new treatment options for KSHV-associated cancers, including Kaposi's sarcoma, primary effusion lymphoma, and HHV8-associated multicentric Castleman disease. (Source: World Pharma News)
Source: World Pharma News - March 1, 2024 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

New Trials in Leukemia/Lymphoma: Could Your Patient Benefit? New Trials in Leukemia/Lymphoma: Could Your Patient Benefit?
Perhaps one of your patients would benefit from enrolling in a new clinical trial in leukemia or lymphoma?Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 28, 2024 Category: Consumer Health News Tags: Hematology-Oncology Source Type: news